share_log

4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Dogan Meeshanthini

4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Dogan Meeshanthini

4/A:持股变动声明(修正)-高管 Dogan Meeshanthini
美股SEC公告 ·  2024/10/07 08:33

Moomoo AI 已提取核心信息

Cardio Diagnostics Holdings, Inc. CEO Dogan Meeshanthini completed a purchase of company stock on September 6, 2024. The transaction involved the acquisition of 68,965 shares of common stock at a price of $0.29 per share. Following this transaction, Meeshanthini's direct holdings in the company increased to a total of 1,655,429 shares. The transaction, characterized as an open market or private purchase, reflects the CEO's direct investment in the company's stock.
Cardio Diagnostics Holdings, Inc. CEO Dogan Meeshanthini completed a purchase of company stock on September 6, 2024. The transaction involved the acquisition of 68,965 shares of common stock at a price of $0.29 per share. Following this transaction, Meeshanthini's direct holdings in the company increased to a total of 1,655,429 shares. The transaction, characterized as an open market or private purchase, reflects the CEO's direct investment in the company's stock.
卡迪欧诊断控股公司首席执行官多甘·梅珊蒂尼于2024年9月6日完成了一笔公司股票交易。该交易涉及以每股0.29美元的价格收购了68,965股普通股。在此交易后,梅珊蒂尼在公司的直接持股增加到总共1,655,429股。这笔交易被称为是公开市场或私人收购,反映了首席执行官对公司股票的直接投资。
卡迪欧诊断控股公司首席执行官多甘·梅珊蒂尼于2024年9月6日完成了一笔公司股票交易。该交易涉及以每股0.29美元的价格收购了68,965股普通股。在此交易后,梅珊蒂尼在公司的直接持股增加到总共1,655,429股。这笔交易被称为是公开市场或私人收购,反映了首席执行官对公司股票的直接投资。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息